- Home
- CZNC vs STRO Comparison
CZNC vs STRO Comparison
Compare CZNC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | STRO |
|---|---|---|
| Founded | 1864 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.7M | 159.5M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CZNC | STRO |
|---|---|---|
| Price | $28.22 | $9.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $47.31 |
| AVG Volume (30 Days) | 60.9K | ★ 319.1K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $16.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.87 | $0.72 |
| 52 Week High | $29.25 | $43.85 |
Technical Indicators
Market Signals| Indicator | CZNC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 38.76 |
| Support Level | $25.09 | $8.11 |
| Resistance Level | $29.25 | $11.80 |
| Average True Range (ATR) | 0.68 | 0.81 |
| MACD | -0.04 | 0.32 |
| Stochastic Oscillator | 48.82 | 50.86 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.